[go: up one dir, main page]

HK1187402A1 - Fen1 as marker for chronic obstructive pulmonary disease (copd) fen1 (copd) - Google Patents

Fen1 as marker for chronic obstructive pulmonary disease (copd) fen1 (copd)

Info

Publication number
HK1187402A1
HK1187402A1 HK14100226.0A HK14100226A HK1187402A1 HK 1187402 A1 HK1187402 A1 HK 1187402A1 HK 14100226 A HK14100226 A HK 14100226A HK 1187402 A1 HK1187402 A1 HK 1187402A1
Authority
HK
Hong Kong
Prior art keywords
fen1
copd
marker
pulmonary disease
chronic obstructive
Prior art date
Application number
HK14100226.0A
Other languages
English (en)
Chinese (zh)
Inventor
Johann Karl
Julia Riedlinger
Norbert Wild
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1187402A1 publication Critical patent/HK1187402A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK14100226.0A 2011-03-11 2014-01-09 Fen1 as marker for chronic obstructive pulmonary disease (copd) fen1 (copd) HK1187402A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11157921 2011-03-11
PCT/EP2012/053841 WO2012123295A1 (fr) 2011-03-11 2012-03-07 Fen1 en tant que marqueur pour une maladie pulmonaire obstructive chronique (copd)

Publications (1)

Publication Number Publication Date
HK1187402A1 true HK1187402A1 (en) 2014-04-04

Family

ID=45808949

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14100226.0A HK1187402A1 (en) 2011-03-11 2014-01-09 Fen1 as marker for chronic obstructive pulmonary disease (copd) fen1 (copd)

Country Status (8)

Country Link
US (2) US20140004544A1 (fr)
EP (1) EP2684053B1 (fr)
JP (1) JP5976692B2 (fr)
CN (1) CN103415771B (fr)
CA (1) CA2826812A1 (fr)
ES (1) ES2583688T3 (fr)
HK (1) HK1187402A1 (fr)
WO (1) WO2012123295A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2583084T3 (es) * 2011-03-11 2016-09-19 F. Hoffmann-La Roche Ag NNMT como marcador para la enfermedad pulmonar obstructiva crónica (EPOC)
CN105695418B (zh) * 2016-03-16 2019-09-10 成都正能生物技术有限责任公司 一种结构特异性核酸酶fen1的单克隆抗体及应用
CN107267658B (zh) * 2017-08-21 2018-11-02 常州市第二人民医院 Copd诊断用分子标志物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
WO2003101283A2 (fr) * 2002-06-04 2003-12-11 Incyte Corporation Marqueurs diagnostiques du cancer du poumon
US20040126784A1 (en) * 2002-07-12 2004-07-01 Rigel Pharmaceuticals, Incorporated Modulators of cellular proliferation
WO2006105252A2 (fr) * 2005-03-28 2006-10-05 The Regents Of The University Of Colorado Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
EP1888779A4 (fr) * 2005-05-20 2009-06-10 Synergenz Bioscience Ltd Méthodes d'analyse de polymorphismes et leurs utilisations
US8927510B2 (en) * 2008-05-16 2015-01-06 Children's Medical Center Corporation Compositions and methods for inhibition of retroviruses
CN102414565B (zh) * 2009-05-04 2014-09-24 霍夫曼-拉罗奇有限公司 作为癌症的标记物的DPPIV/Seprase的用途
CN101930004A (zh) * 2009-06-24 2010-12-29 中国科学院上海生命科学研究院 Apex1用作检测肝细胞癌的蛋白质分子标记的应用
EP2454596B1 (fr) * 2009-07-16 2014-06-11 Roche Diagnostics GmbH Flap endonucléase-1 en tant que marqueur pour le cancer

Also Published As

Publication number Publication date
EP2684053B1 (fr) 2016-05-18
WO2012123295A1 (fr) 2012-09-20
JP2014509738A (ja) 2014-04-21
CN103415771B (zh) 2015-04-22
CN103415771A (zh) 2013-11-27
US20160109461A1 (en) 2016-04-21
CA2826812A1 (fr) 2012-09-20
JP5976692B2 (ja) 2016-08-24
EP2684053A1 (fr) 2014-01-15
US20140004544A1 (en) 2014-01-02
ES2583688T3 (es) 2016-09-21

Similar Documents

Publication Publication Date Title
IL268366A (en) Inhibitors of viral replication
HK1187103A1 (en) Asc as marker for chronic obstructive pulmonary disease (copd) asc (copd)
IL230881A0 (en) Preparations for pulmonary administration containing a eutectic mixture
PL2768479T3 (pl) Zaróbki do kompozycji terapeutycznych zawierających nikotynę
SG11201400580VA (en) Pharmaceutical composition for inhalation
PT2721172T (pt) Marcadores para doença tromboembólica
EP2729755A4 (fr) Système de marquage de points pour tir à l'arc
GB201100114D0 (en) Determing positiion
GB2509634B (en) Maintaining multiple target copies
SMT201600425B (it) Preparazione per colonscopia
EP2671353A4 (fr) Procédés pour atteindre un taux de perte cible
EP2691513A4 (fr) Nouveau marqueur de cardiomyocyte
EP3057609A4 (fr) Procédés de traitement de broncho-pneumopathie chronique obstructive à l'aide du benralizumab
PL2744772T3 (pl) Sposób wytwarzania sewofluranu
EP2706946A4 (fr) Marqueur de positionnement
HK1187104A1 (en) Armet as marker for chronic obstructive pulmonary disease (copd) armet (copd)
HK1187402A1 (en) Fen1 as marker for chronic obstructive pulmonary disease (copd) fen1 (copd)
HK1187675A1 (en) Apex1 as marker for chronic obstructive pulmonary disease (copd) apex1 (copd)
EP2826479A4 (fr) Agent pour faire régresser les maladies pulmonaires obstructives chroniques
HK1187105A1 (zh) 作為慢性阻塞性肺病 的標誌物
HK1190638A1 (zh) 用於犬呼吸道疾病綜合徵的組合物
GB2501403B (en) 3-arylethynyl substituted quinazolinone compounds
IL233568A0 (en) A method for treating obstructive lung disease
HU4133U (en) Arrangement for pavement marker
GB201106870D0 (en) Marker

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200305